Senores Pharma has niche positives, can be a long-term bet
Business Overview
Incorporated in 2017, the company identifies, develops and commercialises speciality and complex niche products in mid-market range. It also undertakes contract manufacturing for its customers. It earns through in-licensing fee, transfer pricing and profit sharing. Over 60% of its revenues come from supplying to regulated markets of the US, Canada and the UK and 32% from emerging markets.
Financials & Growth Prospects
Two acquisitions-Havix and Ratnatris-integrated during FY24. While the company's revenues and net profit for FY24 stood at ₹214 and ₹24.9 crore respectively, the same for six months ended September 2024 stood at ₹181 crore and ₹24 crore respectively. The Ebitda margin too improved from 20.7% to 26% during the same period.
Senores intends to significantly enhance market presence in North America and launch products with potential of NDA approval in the US.
Stock Trading
Dow Theory Made Easy
By — Vishal Mehta, Independent Systematic Trader
Stock Trading
RSI Made Easy: RSI Trading Course
By — Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading
Stock Investing Made Easy: Beginner's Stock Market Investment Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Derivative Analytics Made Easy
By — Vivek Bajaj, Co Founder- Stockedge and Elearnmarkets
Stock Trading
RSI Trading Techniques: Mastering the RSI Indicator
By — Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert
Stock Trading
Futures Trading Made Easy: Future & Options Trading Course
By —
